Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prednisolone sodium phosphate
Drug ID BADD_D01833
Description Prednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]
Indications and Usage For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
Marketing Status Prescription; Discontinued
ATC Code A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID DB14631
KEGG ID D00981
MeSH ID C009022
PubChem ID 441409
TTD Drug ID Not Available
NDC Product Code 50383-040; 52128-164; 42799-812; 65089-0007; 66993-844; 62135-330; 59212-700; 71052-610; 42799-813; 50090-1582; 10695-109; 64958-0042; 0121-0759; 59212-702; 24002-0007; 81646-118; 63187-215; 22552-0051; 66993-846; 24208-715; 0121-0777; 67296-1505; 66993-845; 44523-182; 38779-0153; 65162-667; 50090-0955; 59212-701; 62991-1205; 0121-0773; 68788-7708; 49452-5995; 68791-104; 70166-549; 13925-166; 22552-0004; 17856-0759; 0121-0902; 49452-5996; 60432-212; 51927-0050
Synonyms prednisolone phosphate | Predsol | prednisolone sodium phosphate | prednisolone phosphate, sodium salt, (11beta)-isomer | prednisolone 21-phosphate sodium | prednisolone phosphate sodium | prednisolone phosphate, monosodium salt, (11beta)-isomer | prednisolone-21-phosphate | Pediapred
Chemical Information
Molecular Formula C21H27Na2O8P
CAS Registry Number 125-02-0
SMILES CC12CC(C3C(C1CCC2(C(=O)COP(=O)([O-])[O-])O)CCC4=CC(=O)C=CC34C)O.[Na+].[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Adrenal insufficiency14.11.01.004; 05.01.02.001--
Adrenocortical insufficiency acute14.11.01.020; 05.01.02.005--Not Available
Agitation17.02.05.012; 19.06.02.001--
Alkalosis hypokalaemic14.01.02.002--Not Available
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Angioedema23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Benign intracranial hypertension17.07.02.001--Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Body temperature increased13.15.01.001--Not Available
Carbohydrate tolerance decreased13.02.02.003--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Cataract subcapsular06.06.01.002--Not Available
Constipation07.02.02.001--
Cushing's syndrome24.08.04.001; 19.07.03.002; 14.11.01.007; 05.01.01.001--Not Available
Cushingoid24.08.02.004; 19.07.03.001; 14.11.01.006; 05.01.01.002--
Delusion19.10.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis acneiform23.02.01.004--
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages